Edition:
United States

ProQR Therapeutics NV (PRQR.A)

PRQR.A on American Stock Exchange

11.50USD
15 May 2019
Change (% chg)

-- (--)
Prev Close
$11.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
428
52-wk High
$23.99
52-wk Low
$5.05

Latest Key Developments (Source: Significant Developments)

RTW Investments LP Reports 9.22 Percent Passive Stake In ProQR Therapeutics N.V., As Of Feb 20, 2019
Friday, 22 Feb 2019 05:10pm EST 

Feb 22 (Reuters) - ProQR Therapeutics NV ::RTW INVESTMENTS LP REPORTS 9.22 PERCENT PASSIVE STAKE IN PROQR THERAPEUTICS N.V., AS OF FEB 20, 2019 – SEC FILING.  Full Article

ProQR Reaches Agreement With The FDA On Design Of Phase 2/3 Pivotal Trial For Sepofarsen
Monday, 7 Jan 2019 07:00am EST 

Jan 7 (Reuters) - ProQR Therapeutics NV ::PROQR REACHES AGREEMENT WITH THE FDA ON DESIGN OF PHASE 2/3 PIVOTAL TRIAL FOR SEPOFARSEN (QR-110) FOR LEBER’S CONGENITAL AMAUROSIS 10.PROQR REACHES AGREEMENT WITH THE FDA ON DESIGN OF PHASE 2/3 PIVOTAL TRIAL FOR SEPOFARSEN (QR-110) FOR LEBER’S CONGENITAL AMAUROSIS 10.PROQR THERAPEUTICS NV - TRIAL IS EXPECTED TO START IN FIRST HALF OF 2019.PROQR THERAPEUTICS NV - ANTICIPATE TOP LINE RESULTS FOR BASE-CASE OF 30 TRIAL PARTICIPANTS AROUND YEAR-END 2020..  Full Article

ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
Wednesday, 2 Jan 2019 07:00am EST 

Jan 2 (Reuters) - ProQR Therapeutics NV ::PROQR RECEIVES FAST TRACK DESIGNATION FROM FDA FOR QR-421A FOR USHER SYNDROME TYPE 2.PROQR THERAPEUTICS NV - PRELIMINARY DATA FROM PHASE 1/2 STELLAR CLINICAL TRIAL EXPECTED IN MID-2019.  Full Article

Proqr Announces Strategic Changes To The Management Team And Key New Hires
Thursday, 13 Dec 2018 07:00am EST 

Dec 13 (Reuters) - ProQR Therapeutics NV ::PROQR ANNOUNCES STRATEGIC CHANGES TO THE MANAGEMENT TEAM AND KEY NEW HIRES.PROQR THERAPEUTICS NV - SMITAL SHAH IS PROMOTED TO CHIEF BUSINESS AND FINANCIAL OFFICER.  Full Article

Proqr Q3 Loss Per Share Eur 0.18
Wednesday, 7 Nov 2018 07:00am EST 

Nov 7 (Reuters) - ProQR Therapeutics NV ::PROQR ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2018.Q3 LOSS PER SHARE EUR 0.18.AT SEPTEMBER 30, 2018, PROQR HELD CASH AND CASH EQUIVALENTS OF EUR 113.7 MILLION.  Full Article

Proqr In-Licenses Worldwide Rights To Eye Drug Candidate From Ionis Pharma
Monday, 29 Oct 2018 07:33am EDT 

Oct 29 (Reuters) - ProQR Therapeutics NV ::PROQR IN-LICENSES WORLDWIDE RIGHTS TO OPHTHALMOLOGY DRUG CANDIDATE FROM IONIS PHARMACEUTICALS.PROQR THERAPEUTICS NV - HUMAN PHASE 1/2 CLINICAL TRIAL IN ADRP PATIENTS IS EXPECTED TO START IN 2019.PROQR THERAPEUTICS NV - MADE AN UPFRONT PAYMENT IN ORDINARY SHARES IN AGGREGATE AMOUNT OF $2.5 MILLION, AT $22.23 PER SHARE.PROQR THERAPEUTICS NV - ANNOUNCED SIGNING OF AN AGREEMENT WITH IONIS PHARMACEUTICALS TO LICENSE QR-1123.PROQR THERAPEUTICS - WILL ALSO MAKE FUTURE MILESTONE PAYMENTS, SOME IN EQUITY AND OTHERS IN CASH OR EQUITY AT CO'S DISCRETION.  Full Article

ProQR Q2 Loss Per Share Eur 0.23
Wednesday, 8 Aug 2018 07:00am EDT 

Aug 8 (Reuters) - ProQR Therapeutics NV ::PROQR ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2018.Q2 LOSS PER SHARE EUR 0.23.WITH CURRENT CASH ON HAND OF EUR 33.0 MILLION, AT JUNE 30, 2018, CO'S OPERATION IS FUNDED INTO LATE 2019.  Full Article

ProQR And Galapagos Announce Research Collaboration
Monday, 8 Jan 2018 07:00am EST 

Jan 8 (Reuters) - Galapagos Nv ::PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY.PROQR THERAPEUTICS - UNDER AGREEMENT, TWO COMPANIES WILL WORK TOGETHER TO DISCOVER NOVEL AXIOMER EONS AGAINST FIBROSIS TARGETS SELECTED BY GALAPAGOS.PROQR THERAPEUTICS NV- TARGETS THAT WILL BE PURSUED IN COLLABORATION AND FINANCIAL DETAILS ABOUT COLLABORATION ARE NOT DISCLOSED.  Full Article

Proqr reports loss of EUR 0.42 per share​
Monday, 20 Nov 2017 07:00am EST 

Nov 20 (Reuters) - Proqr Therapeutics Nv :Proqr announces results for the third quarter of 2017.Proqr Therapeutics Nv - ‍net result for three month period ended September 30, 2017 was a EUR 10.5 million loss or EUR 0.42 per share​.  Full Article

ProQR Therapeutics prices public offering
Tuesday, 14 Nov 2017 07:44am EST 

Nov 14 (Reuters) - ProQR Therapeutics Nv :ProQR prices approximately $20 million underwritten public offering and concurrent registered direct offering of ordinary shares.Pricing of offering of its ordinary shares at a price to public of $3.25 per share​.  Full Article